Activist investor’s intervention adds to buzz surrounding BMS.
Speculation mounting that Pfizer and others could try for $90 bn plus merger
French biotech developing cancer immunotherapy with BMS.
Immunotherapy takes on rivals from Roche and BMS.
Tecentriq is latest immunotherapy available on the scheme.
California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Companies to develop bispecific antibodies.